LAWRENCE, Mass., Jan. 24, 2011 /PRNewswire/ — NxStage Medical,
Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products,
today announced the addition of Nancy J. Ham to the Company’s Board
of Directors and the resignation of Jonathan T. Silverstein.
Mr. Silverstein, General Partner of OrbiMed, joined NxStage’s
Board in connection with the Company’s 2008 financing, in which
OrbiMed was the lead investor. “Jonathan has been a
tremendous asset to NxStage helping set the future strategic
direction for the Company,” said Jeff Burbank, Chief Executive
Officer of NxStage Medical. “As we work to further strengthen our
market leadership in renal care, we are excited to add someone of
Nancy’s caliber and industry background to our Board. Nancy is a
strong executive and we look forward to benefiting from her
insights and experience.”
Ms. Ham is currently President, CEO and director of MedVentive,
Inc., a leading provider of physician performance management
solutions for healthcare delivery networks and payers. Previously,
she served as President of Sentillion, Inc. Before joining
Sentillion, Ms. Ham served in various executive capacities at
ProxyMed, Inc., including President and COO, and Healtheon/WebMD
Corporation.
“I’m very excited about contributing to the growth that I
believe NxStage has ahead of them, and to improving patient access
around the world to the many reported benefits of daily home
therapy with the NxStage System One™,” said Ms. Ham.
About NxStage Medical, Inc.NxStage Medical, Inc. (Nasdaq:
NXTM) is a medical device company, headquartered in Lawrence,
Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of End Stage Renal Disease
(ESRD) and acute kidney failure. For mo
‘/>”/>
